Stonegate Capital Partners Updates Coverage on Third Coast Bancshares Inc. (NYSE: TCBX) 2Q25
For 2Q25, Third Coast reported net income of $16.8M, which is up from $13.6M in 1Q25. This was equal to a basic and diluted EPS of $1.12 and $0.96, respectively. The Q/Q increase was primarily attributed to higher net interest income, driven by opportunistic securitization of the portfolio and stability in expenses related to salaries, […]
Stonegate Capital Partners Updates Coverage on BlackSky Technology Inc. (NYSE: BKSY) 1Q25
BKSY reported revenue, adj EBITDA, and EPS of $29.5M, ($0.6)M, and ($0.42), respectively. This compares to our/consensus estimates of $27.6M/$27.2M, $0.7M/$1.5M, and ($0.62)/($0.46). The Imagery and Software Analytical Services segment generated $16.8M in revenue, down from $17.8M in 1Q24. This decrease was primarily due to timing variability in customer project deliveries. The Professional and Engineering […]
Stonegate Capital Partners Updates Coverage on Park-Ohio Holdings Corp (NasdaqGS: PKOH) 1Q25
Park-Ohio Holdings Corp. (NASDAQ: PKOH) has released preliminary earnings for 2Q25, showing a solid performance
Stonegate Capital Partners Updates Coverage On Franklin Covey Co (NYSE: FC) 3Q25
Franklin Covey exhibited performance in-line with expectations during 3Q that was challenged by the external macro environment. While the Company has elaborated on the timing headwinds that caused it to once again lower full year guidance, we view the current situation as a speedbump, noting that the new go-to market strategy, diligent cost cutting, and […]
Stonegate Capital Partners Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) 4Q25
Subsequent to the 2025 year end, Burcon made continued significant progress in its strategic initiatives. The Company successfully scaled up commercial production of its pea protein isolate, marking a pivotal milestone in its go-to-market strategy. This scale up was accomplished at the Company’s Galesburg facility and took less than 90 days. The truncated timeframe enables […]
Stonegate Capital Partners Updates Coverage On Aemetis Inc. (Nasdaq: AMTX) 1Q25
Aemetis’ first quarter results provided the strongest signal to date that the Company is starting to execute on its highest growth business, Dairy RNG. Over the last few years, the Company has invested in and built out one of the nation’s largest networks of dairy renewable gas production (dairy digestors) in California’s Central Valley, a […]
Stonegate Capital Partners Updates Coverage on Hooker Furniture Corporation (NASDAQ: HOFT) 1Q26
HOFT reported revenue, operating income, and adj EPS of $85.3M, ($3.6)M, and ($0.29), respectively. This compares to our/consensus estimates of $92.6M/$88.9M, ($2.5)M/($2.5)M, and ($0.16)/($0.15). It is noted that revenues were slightly below consensus estimates and posted a 8.8% y/y decrease. The decrease was primarily attributed to the decreased volumes and impacts of tariffs on the […]
Stonegate Capital Partners Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) 3Q25
Subsequent to the third quarter of 2025, Burcon made continued significant progress in its strategic initiatives. The Company successfully scaled up commercial production of its pea protein isolate, marking a pivotal milestone in its go-to-market strategy. This scale up was accomplished at the Company’s Galesburg facility and took less than 90 days. The truncated timeframe […]
Stonegate Capital Partners Updates Coverage on Valens Semiconductor Ltd. (NYSE:VLN) 1Q25
Valens Semiconductor achieved robust results in 1Q25, with revenues of $16.8M, surpassing both its prior guidance of $16.3-$16.6M and the previous quarter’s revenue of $16.7M. This marks a significant year-over-year growth from 1Q24 revenue of $11.6M. This performance reflects stabilization and initial recovery in market conditions, with the Company successfully navigating challenges that previously impacted […]
Stonegate Capital Partners Updates Coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL) 3Q25
Incannex Healthcare Inc. (NasdaqGM:IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL). During the third quarter of fiscal year 2025, IXHL reported R&D expenses of $2.74M, down from $3.28M in the same quarter of the previous year, reflecting cost containment measures. SG&A expenses were $2.27M, compared to $4.14M in the prior year, […]